Details of the Drug

General Information of Drug (ID: DMBFYSR)

Drug Name
Hepcidin mab
Indication
Disease Entry ICD 11 Status REF
Anemia 3A00-3A9Z Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0V4YW

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepcidin (HAMP) TTPCG5T HEPC_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Anemia
ICD Disease Classification 3A00-3A9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Hepcidin (HAMP) DTT HAMP 5.37E-01 0.18 0.47
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01340976) A Phase 1 Study of LY2787106 in Cancer and Anemia. U.S. National Institutes of Health.
2 The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161.